EcoDrugPlus

Histone Deacetylase 6

Ensembl ID : ENSPNAG00000006252
Gene Symbol: HDAC6
2 Cross references
181 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSPNAG00000010856
Gene Symbol: HDAC7
3 Cross references
189 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSPNAG00000010413
Gene Symbol: HDAC8
3 Cross references
205 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSPNAG00000029937
Gene Symbol: HCN4
3 Cross references
220 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSPNAG00000014717
Gene Symbol: HCN4
3 Cross references
213 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSPNAG00000006133
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSPNAG00000016879
Gene Symbol: LOC108412872
2 Cross references
147 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSPNAG00000012272
Gene Symbol: LOC108441928
3 Cross references
227 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSPNAG00000000274
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSPNAG00000019568
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSPNAG00000022932
Gene Symbol: LOC108442450
4 Cross references
258 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSPNAG00000001174
Gene Symbol: LOC108432555
4 Cross references
257 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).